Ashish Tyagi
Research Assistant Professor
Contact
Texas A&M Irma Lerma Rangel College of Pharmacy
Mail Stop 1114, 159 Reynolds Medical Building
College Station,
TX
77843
ashishtyagi@exchange.tamu.edu
Phone: 979.436.0294
Education and Training
- Irma Lerma Rangel School of Pharmacy, Associate Research Scientist, , 2022
- University of Louisville, Postdoctoral Scholar, 2021
- Sarvotham Care Ltd., Hyderabad, India, Process Manager, Recombinant Enzyme manufacturing, 2017
- TakaraBio Japan/India, Delhi, India, Process Manager, Recombinant Enzyme manufacturing, , 2014
- H.N.B Garhwal Central University, National Dairy Research Institute, , Ph.D., Biotechnology, 2014
- National Dairy Research Institute, Karnal, India, Senior Research Fellow, 2009
Research Interests
- Development of novel therapeutics for metastatic carcinomas and elucidating their mechanism of action.
- Chemoresistance, repurposing/combination therapy to overcome chemoresistance.
Teaching Interests
- Targeted therapies (Cancer Biology)
- Medical Microbiology, Probiotics: Validation and Scaleup strategies
- Recombinant DNA Technology
Awards, Recognition and Service
- Best Poster Presentation (Faculty) Award: School of Pharmacy, Research Colloquium, 2023.
- Travel Award for Outstanding poster presentation: TiCER (Texas A&M Center for Environmental Health Research) research symposium. 2021
- Best Poster Presentation Award: END2Cancer conference, Oklahoma. 2021.
- Young Investigator Travel Award: American Cancer for Cancer Research-Chinese Society for Clinical Oncology (AACR-CSCO). 2019
- AACR-CSCO Young Investigator Travel Award: for work on a combination of cisplatin and AR signaling inhibitor for treatment of Muscle Invasive Bladder Cancer (MIBC). A 50% reduction in current dose regimen was effective in inhibiting MIBC cell growth and aggressiveness. 2018
- Manufacturer Licensing of two technologies from FSSAI (Food Safety and Standards Authority of India) License no. 10013062000241 for commercial production. 2017
- Young Researcher Award: ICFDF (International conference of Functional Dairy Foods): for Identification of therapeutic interventions through microbiome manipulation as possible route to increase anti-cancerous Conjugated Linoleic Acid (CLA) concentration in ruminant derived food products. 2011
Patents
- PCT (Ser. No. PCT/US2021/018119). SMALL MOLECULE REGULATORS OF NOTCH1 AND USES THEREOF. Arun Kumar Sharma, Ashish Tyagi, Chendil Damodaran. 2021
Representative Publications
- Ashish Tyagi, Balaji Chandrasekaran, Ajit K. Navin, Vaibhav Shukla, Becca V. Baby, Murali K. Ankem, Chendil Damodaran. 2023. Molecular interplay between NOX1 and autophagy in cadmium-induced prostate carcinogenesis, Free Radical Biology and Medicine, 199, 44-55.
- Uttara Saran, Balaji Chandrasekaran, Ashish Tyagi, Vaibhav Shukla, Amandeep Singh, Arun K Sharma and Chendil Damodaran. 2023. A small molecule Inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth. Frontiers in Pharmacology. 14:1150774.
- Uttara Saran#, Ashish Tyagi#, Balaji Chandrasekaran, Murali K Ankem, Chendil Damodaran. 2021. The role of autophagy in metal-induced urogenital carcinogenesis. Seminars in cancer biology. 76. 247-257.
- Ashish Tyagi, Balaji Chandrasekaran, Venkatesh Kolluru, Becca V Baby, Cibi A Sripathi, Murali K Ankem, Srinivasa R Ramisetti, Venkat R Chirasani, Nikolay V Dokholyan, Arun K Sharma, Chendil Damodaran. 2020, ASR490, a Small Molecule, Overrides Aberrant Expression of Notch1 in Colorectal Cancer. Molecular Cancer Therapeutics 19(12):2422-2431
- Ashish Tyagi, Arun K Sharma, Chendil Damodaran. 2020. A review on notch signaling and colorectal cancer. Cells. 9(6). 1549.
- Ashish Tyagi#, Deeksha Pal#, Balaji Chandrasekaran, Murali Ankem, Arun Sharma and Chendil Damodaran. 2018, Suppression of Notch1 and AKT Mediated Epithelial to Mesenchymal Transition by Verrucarin J in Metastatic Colon Cancer. Cell death & disease. 9(8), 798.